Letters, Testimony & Comments

August 5, 2011
BEFORE THE CALIFORNIAENVIRONMENTAL PROTECTION AGENCY AIR RESOURCES BOARD     Comments of Biotechnology Industry Organization on     DRAFT LCFS Sustainability Principles, Criteria, Indicators Principles 4, 5, 6...
August 2, 2011
Dear Senators Reid and McConnell and Representatives Boehner and Pelosi: We are deeply concerned about recent action in the U.S. House of Representatives to amend H.R. 2112, the Fiscal Year 2012 Agriculture, Rural Development, Food and Drug...
August 1, 2011
RE:     June 29, 2011 Memorandum on Proposed Changes to the Medicare Coverage Gap Discount Program – Low-Volume Claims and Clarifications The Biotechnology Industry Organization (BIO) appreciates this opportunity to...
July 29, 2011
  BIO fully supports the creation of an infectious disease standard by the Occupational Safety and Health Administration (OSHA) to protect healthcare workers (HCWs), and BIO believes that vaccinations should be an integral part of this...
July 28, 2011
The Biotechnology Industry Organization (BIO) is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,100 members worldwide. BIO members are involved in the...
July 25, 2011
The Honorable Michael J. Rogers 133 Cannon HOB U.S. House of Representatives Washington, DC 20515 Dear Representative Rogers: On behalf of the Biotechnology Industry Organization (BIO), I am writing with our support for H.R. 2405, the...
July 25, 2011
BIO supports policies that emphasize disclosure of financial interests, rather than prohibiting certain relationships. It is important to recognize that relationships between industry and researchers have had an enormously beneficial impact on...
July 23, 2011
BIO commends the FDA for prospectively seeking input from industry to ensure that the regulatory environment is supportive of the rapid technological advancement of clinical diagnostic applications. The approach to assessing the analytical...
July 19, 2011
BIO’s comments addressed maters such as HRSA’s application of the exclusion, operational concerns arising from the proposed interpretation, and covered entity compliance and documentation requirements.   
July 12, 2011
BIO sent a letter to U.S. House and Senate leaders commending Congress for its bipartisan support for the commercialization of renewable fuels and, in particular, advanced biofuels. In the letter, BIO stresses that Section 526 of the Energy...
July 12, 2011
BIO views this Draft Guidance as an important step in further implementing a process for safety labeling changes that ensures patients and their physicians have access to timely, relevant, and science-based prescribing information to make informed...
July 8, 2011
In this brief filed jointly with the Association of University Technology Managers and CropLife International, BIO explains that the current high burden of proof for invalidating a patent in court has deep historic roots in Supreme Court law, and...
July 7, 2011
Paul Hastings, testifying on behalf of BIO, discussed the importance of biotechnology in providing cures to diseases, and creating high-paying jobs. In his testimony, Mr. Hastings, demonstrated how regulatory uncertainty, longer drug development...
July 5, 2011
In the brief filed in support of neither party, BIO asserts that the existing Federal Circuit standard of liability for infringing a process patent when the steps of the patented process are practiced by multiple different entities is too...
July 5, 2011
BIO agrees with CMS that the proposed influenza vaccination standard will help increase vaccination coverage among patients, thereby reducing influenza morbidity and mortality. We also recommend that CMS include pneumonia vaccination and pertussis...
June 28, 2011
Today I'd like to tell you what we've been doing at BIO lately—we've been imagining. We've been imagining not just how biotechnology can heal, fuel, and feed the world—– but how we at BIO can make that happen...
June 27, 2011
Today, biotechnology companies have more than 600 new biologic medicines in development and biotechnology is behind about two-thirds of the new medicines in development. However, continued advancement in biotechnology and the life sciences...
June 23, 2011
BIO’s testimony details how the growth of agricultural biotechnology has provided numerous benefits to farmers, consumers and the environment, and highlights the potential for agricultural biotechnology to meet future demands and global...